Article in Journal of neurochemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
9 authors at 5 institutions in 2 countries.
In-Young ChoiHoglund Biomedical Imaging Center, University of Kansas Medical Center (KUMC), Kansas City, Kansas, USA.ORCID 0000-0002-1489-4119
Wen-Tung WangHoglund Biomedical Imaging Center, University of Kansas Medical Center (KUMC), Kansas City, Kansas, USA.
Bhumsoo KimDepartment of Neurology, University of Michigan, Ann Arbor, Michigan, USA.
Junguk HurDepartment of Biomedical Sciences, University of North Dakota, Grand Forks, North Dakota, USA.
David C RobbinsDepartment of Medicine, KUMC, Kansas City, Kansas, USA.
Dae-Gyu JangDepartment of Neurology, University of Michigan, Ann Arbor, Michigan, USA.
Masha G SavelieffDepartment of Biomedical Sciences, University of North Dakota, Grand Forks, North Dakota, USA.ORCID 0000-0001-5575-2494
Eva L FeldmanDepartment of Neurology, University of Michigan, Ann Arbor, Michigan, USA.ORCID 0000-0002-9162-2694
Phil LeeHoglund Biomedical Imaging Center, University of Kansas Medical Center (KUMC), Kansas City, Kansas, USA.ORCID 0000-0002-2087-8887
University of Michigan · USRehabilitation Institute of Kansas City · USUniversity of North Dakota · USKansas City Kansas Community College · USUniversity of Kansas Medical Center · US
Funding
Research BaseP30DK092926 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MARY ELLEN MICHELE HEISLER, ADESUWA B OLOMU · 2011 to 2026
$10.0M
WRITING AND WT LOSS MAINTENANCEM01RR023940 · NCRR · UNIVERSITY OF KANSAS MEDICAL CENTER · PI LEIDY, HEATHER J · 2007 to 2009
$6.6M
Schwann Cell Senescence and the Secretome Provide a Unifying Mechanism for the Onset and Progression of Diabetic NeuropathyR01DK130913 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Eva Lucille Feldman, Junguk Hur · 2022 to 2026
$3.3M
Targeting Inflammation with Salsalate as a Novel Therapy for Diabetic NeuropathyR01DK107956 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BUSUI (POP-BUSUI), RODICA, FELDMAN, EVA LUCILLE · 2016 to 2020
$3.0M
Identifying lifelong factors that impact brain health and outcomes in type 1 diabetes: The Cognition and Longitudinal Assessments of Risk Factors over 30 Years (CLARiFY) Diabetes Complications StudyR01DK129320 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI FELDMAN, EVA LUCILLE · 2021 to 2025
$2.3M
Quantitative in vivo biomarkers of oxidative stress in diabetesR21DK081079 · NIDDK · UNIVERSITY OF KANSAS MEDICAL CENTER · PI CHOI, IN-YOUNG · 2008 to 2009
$404k
Andrea and Lawrence A. Wolfe Brain Health InitiativeJuvenile Diabetes Research Foundation United Kingdom 5COE-2019-861-S-BNathan and Rose Milstein Research FundNCRR NIH HHS M01 RR023940NeuroNetwork for Emerging TherapiesNIDDK NIH HHS P30 DK092926NIDDK NIH HHS R01 DK107956NIDDK NIH HHS R01 DK129320NIDDK NIH HHS R01 DK130913NIDDK NIH HHS R21 DK081079NIH HHS M01RR023940NIH HHS R01DK107956NIH HHS R01DK129320NIH HHS R01DK130913NIH HHS R21DK081079Robert and Katherine Jacobs Environmental Health InitiativeRobert E. Nederlander Sr. Program for Alzheimer's ResearchSinai Medical Staff Foundation Research on Studying Diet and Brain Health
6 · The paper itself
Abstract
Type 2 diabetes (T2D) is a complex chronic metabolic disorder characterized by hyperglycemia because of insulin resistance. Diabetes with chronic hyperglycemia may alter brain metabolism, including brain glucose and neurotransmitter levels; however, detailed, longitudinal studies of metabolic alterations in T2D are lacking. To shed insight, here, we characterized the consequences of poorly controlled hyperglycemia on neurochemical profiles that reflect metabolic alterations of the brain in both humans and animal models of T2D. Using in vivo
Indexed as
BrainDiabetes Mellitus, Type 2AgedAnimalsFemaleGlucoseHumansMagnetic Resonance SpectroscopyMaleMiceMice, Inbred C57BLMiddle AgedProton Magnetic Resonance SpectroscopyGlucosebrain metabolismhuman brainmagnetic resonance spectroscopymouseneurochemical profiletype 2 diabetes
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Non-invasive in vivo measurements of metabolic alterations in the type 2 diabetic brain by · full record | OpenQuestion